Key Takeaways
- • Hospital 30-day readmission rates for COPD patients increased following private equity acquisition, according to research presented at the American Thoracic Society International Conference in May 2026.
- • In-hospital mortality for pneumonia patients worsened at hospitals acquired by private equity firms, indicating potential quality-of-care deterioration post-acquisition.
- • Dr. Stephen Mein, pulmonologist at Beth Israel Deaconess Medical Center and researcher at the Richard A. and Susan F. Smith Center for Outcomes Research, highlighted findings as evidence of "growing concerns around the potential negative effects of private equity ownership in health care."
- • The research underscores the need for regulatory scrutiny of healthcare acquisitions as private equity deal activity in the hospital sector continues to accelerate.
Summary
Researchers analyzing hospital performance metrics have identified measurable quality declines in respiratory care following private equity acquisitions, raising fresh concerns about operational and clinical outcomes in consolidating healthcare markets.
Data presented at the American Thoracic Society International Conference documented a rise in 30-day hospital revisits for chronic obstructive pulmonary disease (COPD) encounters at facilities that underwent private equity ownership transitions. Concurrently, the same hospitals experienced worsening in-hospital mortality rates for pneumonia cases, suggesting systemic changes in care delivery or resource allocation post-acquisition.
Dr. Stephen Mein, a pulmonologist at Beth Israel Deaconess Medical Center and outcomes researcher at the Richard A. and Susan F. Smith Center for Outcomes Research, characterized the findings as statistically significant evidence of negative effects tied to private equity management. "Our findings add to growing concerns around the potential negative effects of private equity ownership in health care and highlight the need for stronger regulations of these acquisitions to help protect our patients," Mein stated to Healio.
The timing of this research is strategically significant for institutional investors and healthcare-focused funds evaluating acquisition targets. Private equity acquisitions of hospitals have accelerated in recent years, expanding the potential patient impact. Mein noted that "the results could have implications for a number of patients across the U.S. as private equity acquisitions of hospitals are increasing in recent years," signaling broader systemic concerns rather than isolated operational failures.
The research provides quantifiable metrics—readmission rates and mortality figures—that diverge from the operational efficiency narratives typically presented in private equity healthcare deal theses. These findings may influence future regulatory frameworks governing healthcare consolidation and could affect valuation multiples and deal structures in the hospital acquisition market.
Data presented at the American Thoracic Society International Conference documented a rise in 30-day hospital revisits for chronic obstructive pulmonary disease (COPD) encounters at facilities that underwent private equity ownership transitions. Concurrently, the same hospitals experienced worsening in-hospital mortality rates for pneumonia cases, suggesting systemic changes in care delivery or resource allocation post-acquisition.
Dr. Stephen Mein, a pulmonologist at Beth Israel Deaconess Medical Center and outcomes researcher at the Richard A. and Susan F. Smith Center for Outcomes Research, characterized the findings as statistically significant evidence of negative effects tied to private equity management. "Our findings add to growing concerns around the potential negative effects of private equity ownership in health care and highlight the need for stronger regulations of these acquisitions to help protect our patients," Mein stated to Healio.
The timing of this research is strategically significant for institutional investors and healthcare-focused funds evaluating acquisition targets. Private equity acquisitions of hospitals have accelerated in recent years, expanding the potential patient impact. Mein noted that "the results could have implications for a number of patients across the U.S. as private equity acquisitions of hospitals are increasing in recent years," signaling broader systemic concerns rather than isolated operational failures.
The research provides quantifiable metrics—readmission rates and mortality figures—that diverge from the operational efficiency narratives typically presented in private equity healthcare deal theses. These findings may influence future regulatory frameworks governing healthcare consolidation and could affect valuation multiples and deal structures in the hospital acquisition market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.